• Wondering whether Globus Medical at around US$79.78 is priced for its future potential or already running ahead of itself? This breakdown can help you frame the stock's current value with more clarity.
• The share price has pulled back recently, with the stock down about 5.9% over the past week and 12.7% over the past month, even though the 1 year return stands at 35.3% and the 3 year return at 43.9%.
• Alongside this recent performance, Globus Medical has been in the spotlight as investors reassess medical equipment stocks and update expectations for companies exposed to spine and musculoskeletal treatments. This backdrop helps explain why some investors may now be rethinking what counts as a reasonable price for the stock.
• On Simply Wall St's 6 point valuation checklist, Globus Medical currently scores a full 6 out of 6. The sections ahead will walk through what that means using different valuation methods, then finish with a discussion of a broader way to think about valuation beyond any single model.

Approach 1: Globus Medical Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s value, giving an estimate of what the business might be worth based on those cash flows alone.

For Globus Medical, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow stands at about $620.8 million. Analyst and extrapolated forecasts used in the model include projected Free Cash Flow of $449.4 million in 2026, $664.2 million in 2027, and $785.6 million in 2028, all in $. Simply Wall St then extends these out to 2035 using its own assumptions to build a 10 year cash flow stream.

Discounting these projected cash flows back to today gives an estimated intrinsic value of $155.12 per share, compared with the recent share price of about $79.78. On this basis, the DCF output suggests the stock trades at a 48.6% discount. This indicates that the model implies meaningful upside potential if the cash flow projections are met.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Globus Medical is undervalued by 48.6%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Approach 2: Globus Medical Price vs Earnings

For profitable companies, the P/E ratio is a useful shorthand because it links what you pay for the stock to the earnings that support that price. It also tends to reflect what the market is currently willing to pay for each dollar of profit.

In practice, higher expected earnings growth and lower perceived risk usually support a higher P/E ratio, while slower growth and higher risk are often associated with a lower P/E. So context matters when deciding whether a given P/E level looks stretched or conservative.

Globus Medical currently trades on a P/E of about 18.46x. That sits below the Medical Equipment industry average of about 24.23x and also below the peer group average of roughly 42.86x. Simply Wall St’s “Fair Ratio” for Globus Medical is 23.65x. This is a proprietary estimate of what the P/E might reasonably be given factors such as earnings growth, industry, profit margins, market cap and specific risks.

This Fair Ratio can be more informative than a simple comparison with industry or peers because it adjusts for company specific characteristics rather than treating all stocks as directly comparable. Since Globus Medical’s current P/E of 18.46x is below the Fair Ratio of 23.65x, the multiple based assessment points to the stock trading below that fair level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Globus Medical Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced as a simple way for you to attach a story about Globus Medical to the numbers you see, linking your view of its future revenue, earnings and margins to a Fair Value that can then be compared with the current share price.

On Simply Wall St’s Community page, Narratives are an accessible tool used by millions of investors. Your chosen assumptions flow directly into a forecast and Fair Value, and that Fair Value is automatically updated when fresh information, like earnings or news, is added to the system.

For Globus Medical, one investor might align with a more optimistic Narrative that points to a Fair Value of US$123.0 per share, while another might prefer a more cautious Narrative closer to US$65.0. By comparing each Fair Value to the current price you can decide whether the stock looks closer to your definition of expensive or attractive based on the story you believe.

Do you think there's more to the story for Globus Medical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.